# BPC-157 Dosage in the Research: Per-Kg Animal Figures and PK, Reviewed > BPC-157 dosage as the literature expresses it: per-body-weight animal figures, routes studied, and the under-30-minute half-life. Research context only, cited to source. How animal studies report doses, which routes were tested, and what the pharmacokinetics show — described, not prescribed. ## How BPC-157 Doses Are Expressed in the Literature BPC-157 dosage in the research record is expressed by body weight in animals, not as a human regimen. Rodent studies commonly report figures around 10 microg/kg and 10 ng/kg, and some tendon work has gone as low as 10 pg per rat [1]. Gastric-ulcer cytoprotection was studied specifically at 400 ng/kg and 800 ng/kg in rats [4]. These are animal-model figures, and they are presented here strictly as how the studies described their dosing — not as a recommendation for any person. The human exposures that exist are limited to pilot protocols: a two-person IV safety pilot used 10 mg then 20 mg by one-hour infusion [11], and a separate intravesical interstitial-cystitis pilot used a single 10 mg dose during cystoscopy [13]. No study establishes a safe or effective human dose, and this digest grades any human-dosing claim as NO HUMAN DATA. ## BPC-157 Half-Life and Clearance BPC-157 half life is short, and it is one of the few BPC-157 properties characterized with real pharmacokinetic rigor. The first formal PK/ADME characterization reported an elimination half-life under 30 minutes for the peptide in rats and dogs, across intravenous and intramuscular routes, with linear pharmacokinetics and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [2]. Intramuscular bioavailability was roughly 14-19% in rats and 45-51% in dogs, with excretion via urine and bile [2]. The practical reading is that the molecule does not accumulate. Reported tissue effects in animal repair models accrue over repeated dosing across days, not from a single long-lived exposure [1]. That distinction matters for interpreting the literature: an outcome that builds over a week of daily dosing is a biological repair response, not the signature of a drug that lingers in circulation. This is graded ESTABLISHED animal pharmacokinetics — characterized, reproducible, and clearly bounded to the species studied. What it does not tell us is the human picture, because no validated human pharmacokinetic study has been published [12]. ## Routes Studied and Stability The routes in the literature span intraperitoneal (most common in rodent work), intramuscular, intragastric and peroral, local or intra-lesional, and — in the human pilots only — intravenous, intravesical, and intra-articular [11][13][10]. The breadth reflects how widely the peptide has been probed in animals, not a consensus on any one clinical route, and route mattered to outcomes: in the gastric-ulcer work, intramuscular delivery outperformed intragastric [4]. A reviewed reading does not flatten that into 'it works' — the same compound performed differently depending on how it was given. The 'stable gastric pentadecapeptide' descriptor underlies interest in oral and peroral routes, because the peptide is reported stable in human gastric juice, and animal ulcer work dosed it intragastrically [4]. Stability in the stomach is a genuine, characterized laboratory property; it is not, on its own, evidence that an oral dose reaches the bloodstream intact or produces an effect in a person. Formal human oral pharmacokinetics are not established [12], so oral efficacy in people remains unproven, and the gap between 'survives gastric juice' and 'works taken by mouth' is exactly the kind of distinction this digest is built to hold. Reconstitution and storage practices discussed in research contexts are laboratory handling notes, not validated clinical protocols, and nothing here should be read as a preparation or administration instruction. ## How Long Should I Stay on BPC-157? There is no validated human duration. Research doses are expressed per body weight in animals, often around 10 microg/kg [1], and the only human exposures on record are single-session or two-day pilot protocols [11]. No study establishes a safe or effective course length in people, which is why this question is graded NO HUMAN DATA throughout the digest. The animal healing timelines that do exist run over days to weeks of repeated dosing, reflecting a biological repair process rather than a fixed regimen [1]. Because the peptide clears quickly, with an elimination half-life under 30 minutes in animals [2], the question of 'how long to stay on it' has no pharmacologic answer the literature can supply — there is no steady-state human exposure that has been studied to recommend continuing or stopping. The honest position is that duration, like human dose, is simply uncharacterized. --- Each BPC-157 finding here is graded by how far the evidence actually reaches — established in animals, pilot-only in humans, or no human data at all — and the FDA 503A status is read first; reviewed by no clinic, and nothing here is dispensed or sold.